Pictet Asset Management Holding SA Sells 46,394 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Pictet Asset Management Holding SA lowered its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 11.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 354,455 shares of the biopharmaceutical company’s stock after selling 46,394 shares during the quarter. Pictet Asset Management Holding SA owned approximately 0.62% of Agios Pharmaceuticals worth $11,647,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of AGIO. Venturi Wealth Management LLC purchased a new stake in shares of Agios Pharmaceuticals in the 4th quarter worth $33,000. Wingate Wealth Advisors Inc. bought a new position in Agios Pharmaceuticals during the 4th quarter worth about $53,000. KBC Group NV increased its position in Agios Pharmaceuticals by 30.5% during the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company’s stock valued at $86,000 after purchasing an additional 611 shares during the period. Quantbot Technologies LP bought a new stake in shares of Agios Pharmaceuticals in the 3rd quarter valued at about $146,000. Finally, AlphaQuest LLC lifted its position in shares of Agios Pharmaceuticals by 106.2% in the 4th quarter. AlphaQuest LLC now owns 4,540 shares of the biopharmaceutical company’s stock worth $149,000 after purchasing an additional 2,338 shares during the period.

Insider Buying and Selling at Agios Pharmaceuticals

In related news, insider Tsveta Milanova sold 2,804 shares of Agios Pharmaceuticals stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $32.18, for a total transaction of $90,232.72. Following the completion of the sale, the insider now owns 18,906 shares of the company’s stock, valued at $608,395.08. The trade was a 12.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 4.93% of the company’s stock.

Agios Pharmaceuticals Stock Up 3.8 %

Shares of Agios Pharmaceuticals stock opened at $28.44 on Thursday. The company has a 50 day moving average price of $32.88 and a 200 day moving average price of $40.49. The firm has a market capitalization of $1.63 billion, a P/E ratio of 2.51 and a beta of 0.90. Agios Pharmaceuticals, Inc. has a 52 week low of $26.66 and a 52 week high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. As a group, research analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. Royal Bank of Canada lifted their price objective on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a report on Tuesday, December 10th. Scotiabank boosted their price target on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a research report on Monday, December 9th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. StockNews.com lowered shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, February 14th. Finally, HC Wainwright started coverage on shares of Agios Pharmaceuticals in a research report on Monday, February 24th. They issued a “buy” rating and a $58.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $56.57.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.